It seems unlikely that a new reimbursed option will be introduced to the early breast cancer environment anytime soon.

First, Lilly Korea again failed to overcome the barrier of the Health Insurance Review and Assessment Service's Cancer Disease Review Committee for its CDK4/6 inhibitor Verzenio (abemaciclib). This was the company’s second failed attempt to receive reimbursement for the drug in Korea.

Verzenio was the only new drug available for HR+/HER2- breast cancer other than the endocrine therapy letrozole generic.

In the field of early-stage breast cancer, Lilly Korea faced challenges in presenting Verzenio’s reimbursement to be deliberated by the Drug Reimburseme